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Abstract
Mitral valve regurgitation is a challenging clinical condition that is frequent, highly varied, and 
poorly understood. While the causes of mitral regurgitation are multifactorial, how the 
hemodynamics of regurgitation impact valve tissue remodeling is an understudied phenomenon. 
We employed a pseudo-physiological flow loop capable of long-term organ culture to investigate 
the early progression of remodeling in living mitral valves placed in conditions resembling mitral 
valve prolapse (MVP) and functional mitral regurgitation (FMR). Valve geometry was altered to 
mimic the hemodynamics of controls (no changes from native geometry), MVP (5mm 
displacement of papillary muscles towards the annulus), and FMR (5mm apical, 5mm lateral 
papillary muscle displacement, 65% larger annular area). Flow measurements ensured moderate 
regurgitant fraction for regurgitation groups. After 1-week culture, valve tissues underwent 
mechanical and compositional analysis. MVP conditioned tissues were less stiff, weaker, and had 
elevated collagen III and glycosaminoglycans. FMR conditioned tissues were stiffer, more brittle, 
less extensible, and had more collagen synthesis, remodeling, and crosslinking related enzymes 
and proteoglycans, including decorin, matrix metalloproteinase-1, and lysyl oxidase. These 
models replicate clinical findings of MVP (myxomatous remodeling) and FMR (fibrotic 
remodeling), indicating that valve cells remodel extracellular matrix in response to altered 
mechanical homeostasis resulting from disease hemodynamics.
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Introduction
Mitral valve regurgitation is an insidious, frequent, and heterogeneous condition with a lack 
of fundamental knowledge about how this disease starts, progresses, or could be reversed or 
prevented. Despite a wide variety of clinical presentations, all mitral regurgitation is 
accompanied by a distortion of valve geometry, resulting in valves experiencing an altered 
hemodynamic profile. These alterations change the mechanical forces the valves experience 
throughout the cardiac cycle.25,29,38 It has been previously shown that valve interstitial cells 
are sensitive to changing mechanical environments, and that changes in strain can alter the 
types of extracellular matrix proteins that valve interstitial cells produce and degrade.33,34 In 
light of these findings, it is clear that the impact of altered regurgitation hemodynamics on 
the remodeling of valve tissues throughout the progression of mitral regurgitation is an 
understudied phenomenon.
The two main types of mitral regurgitation result in vastly different hemodynamic profiles, 
and the valves in each experience very different mechanical forces. Organic mitral 
regurgitation typically takes the form of mitral valve prolapse (MVP). MVP is associated 
with slack tissues, resulting in decreased tension experienced by valve components.24,27 
MVP is also associated with the mechanical weakening of valve tissues, including leaflets 
and chordae tendineae, as well as an accumulation of glycosaminoglycans (GAGs) and 
proteoglycans within tissues, a process known as myxomatous remodeling.22 MVP is 
multifactorial, with a variety of molecular and genetic factors altered across different patient 
populations with the disease.14 Despite new insight into potential genetic or molecular 
mechanisms of myxomatous degeneration, there remain gaps in our knowledge of how MVP 
initiates and progresses.14
The second type of regurgitation, functional mitral regurgitation (FMR), develops as a result 
of the distortion of the valve annulus and papillary muscle geometry that occurs in regional 
or global left ventricular systolic dysfunction.44 The altered geometry creates higher tension 
forces throughout the leaflets and chordae of the valve, resulting in leaflet tethering.25,29 
Tethering prevents appropriate valve coaptation during systole, resulting in backflow. 
Overall, FMR is associated with stiffer, more fibrotic tissues.19,20
These two disease processes represent not only the different etiologies of mitral 
regurgitation, but also the extremes of functional disturbance and altered geometry. Despite 
the detailed findings of studies into the mechanical and compositional properties of both 
end-stage MVP and FMR tissues,19–22 how the altered mechanical environment of 
regurgitation directly impacts these properties remains poorly understood. By understanding 
the impact of the extremes of high and low tension, we gain an appreciation for the valve 
interstitial cell response to altered mechanics and the impact mechanics has on the 
progression of mitral regurgitation.
Our group has designed a pseudo-physiologic flow loop system, the Rice University Flow 
Loop System (RUFLS), capable of long-term in vitro culture of living mitral valves.18 Here 
we document the ability to recreate the hemodynamic environment of both MVP and FMR 
in vitro using RUFLS. We then explore how the resulting altered mechanics affect valve 
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interstitial cell remodeling of the underlying extracellular matrix and posit that the 
differences observed in the tissue characteristics of these two disease conditions are 
influenced by the natural responses of cells to altered tension.
Materials and Methods
Organ Culture System
The design and operation of the core components of RUFLS have been described 
previously.17,18 In brief, adolescent (6 to 9 month) porcine mitral valves obtained from a 
local abattoir (Fisher’s Ham and Meats, Spring, TX) are harvested intact and installed into a 
mitral valve holder. This mitral holder is then placed into a mock left ventricular chamber. 
The left ventricular chamber is comprised of a culture medium compartment and an air 
compartment separated by a silicone membrane. LabView software (National Instruments, 
Austin, TX) powers a proportional pressure regulator (Numatics, Novi, MI) that creates a 
high-pressure systolic waveform that forces media through a mechanical aortic valve and 
into the flow loop. Other loop components include a compliance chamber, which dampens 
the systolic pressure wave, and a reservoir chamber, which holds media until it flows by 
gravity back through the mitral valve for a low-pressure filling phase and has an attached air 
filter for air exchange within the system. The system creates a complete mock cardiac cycle 
with physiological waveforms and pressures, with a flow rate of 3 liters per minute. For this 
study, approximately 1.2 L of M199 culture medium (Sigma-Aldrich, St Louis, MO) 
supplemented with 10% bovine growth serum (ThermoHyclone, Logan, UT) and 2% anti-
microbial solution (Mediatech, Manassas, VA) was pumped through each loop at a rate of 60 
beats per minute and a systolic pressure of 125mmHg. The system was placed in a standard 
cell culture incubator at 37°C and 5% CO2. A schematic of the system is shown in Figure 1.
Imaging Flow Loop
A second, non-sterile, imaging flow loop, described in detail previously,35,36 was used to 
visualize valve movement and hemodynamics of control and disease models cultured in 
RUFLS. This system was augmented to allow for installation of intact mitral valves within 
its mock left ventricular chamber using the same attachment mechanisms as RUFLS. Using 
this flow loop, we recreated flow conditions of moderate mitral regurgitation in order to 
confirm the functional abnormalities of each mitral regurgitation condition. Incorporated 
into this system were imaging windows capable of visualization and ultrasound, including 
color Doppler echocardiography (2 to 4 MHz transducer, Sonos 7500, Philips Medical 
Systems, Bothell, Washington), at standard anatomic positions and distance.
Creation of Experimental Culture Conditions
Improvements to the organ culture system since it was first published,17 allow for precise 
control of the position of the papillary muscles independently along both the apical-basal 
and medial-lateral axes (Supplemental Figure 1). Prior to harvest, papillary muscle position 
was determined by measuring the distance to the corresponding valve commissure in both 
the apical-basal and the medial-lateral axes. For the purposes of papillary muscle positioning 
it was assumed the papillary muscles were positioned directly below the commissures along 
the anterior-posterior axis. The annular size of the mitral valve was then determined using a 
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Duran AnCore annuloplasty ring sizing kit (Medtronic, Minneapolis, MN). These 
measurements were considered the neutral position of the valve apparatus and were 
replicated for control models.
To create the slack chordae and low tension associated with MVP, harvested valves were 
first placed in the neutral position and then both papillary muscles were displaced 5 mm 
basally, towards the annulus.
To create the high-tension tissues associated with FMR, harvested valves were first sewn 
onto annular rings approximately 65% larger by area than control annuli. This greater area 
included a 10% greater commissure-to-commissure dimension and a 50% greater anterior-
posterior annular measurement. These altered dimensions were based on a variety of clinical 
findings comparing patients with FMR to controls7,20,39 and values used to create in vitro 
FMR.11,25,37 The harvested valves were then placed in the neutral position and papillary 
muscles were displaced 5 mm apically, away from the valve annulus, and 5 mm laterally, 
creating the high-tension tethering of FMR. These displacements have been previously 
shown to elevate tension on anterior strut, posterior basal, and commissural chordae, thereby 
increasing leaflet tenting and regurgitation.25,29 Alterations in valve geometry for both MVP 
and FMR models can be seen in Figure 2.
All models were cultured in RUFLS for one week and monitored for regurgitant flow and 
cardiac output using an ultrasonic meter (Transonic Systems, Ithaca, NY). After culture, 
select valves were imaged using both video and color Doppler echocardiography in our 
imaging flow loop to characterize regurgitant flow of different models. All valves were then 
sectioned with leaflets divided into either radial or circumferential direction sections as seen 
in Figure 3. Radial dissection resulted in anterior radial and posterior radial leaflet segments 
and anterior basal, anterior marginal, posterior basal, and posterior marginal chordae for use 
in mechanical and histological studies. Circumferential sections resulted in anterior clear 
zone, anterior rough zone, and posterior circumferential sections along with the chordal 
sections for use in mechanical and biochemical testing.
Validation of Viability of Control Condition Tissues
To verify that improvements made to the RUFLS system did not affect tissue viability, a 
series of assays were performed as described previously.18 Fresh porcine mitral valves were 
obtained and sections were compared to control conditioned tissues cultured for 1 week to 
ensure viability of tissues within the system (n = 6). DNA content was assessed using 
fluorescent Picogreen dye (Invitrogen, Grand Island, NY) and valve layer structure was 
analyzed by Movat pentachrome stain. In addition, to ensure the viability of cells from 
cultured valves, cells were isolated from control condition valve leaflets and cultured on 
tissue culture plastic for 2 weeks as previously described.45
Histological Staining and Immunohistochemistry
Radial sections reserved for histology or immunohistochemistry were formalin-fixed, 
paraffin embedded, and sectioned into 5 μm thick sections. Tissue sections from each 
condition were then stained according to previously described methods using a Herovici 
stain, used to differentiate between young collagen, stained blue, and mature collagen, 
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stained red.26 Picrosirius red staining was used to assess collagen alignment according to the 
color observed under polarized light with more aligned collagen producing longer 
wavelengths (i.e. red) of birefringence.13,30
Immunohistochemistry analysis was performed using techniques previously described.46 
This analysis allowed for localization of several markers of tissue phenotype and collagen 
remodeling, including collagen III (ab7778; Abcam, Cambridge, England), matrix 
metalloproteinase-1 (MMP-1; ADI-905-472-1, Enzo Life Sciences, Farmingdale, NY), 
decorin (LF # 136, Gift from Dr. Larry Fisher, NIH),15 lysyl oxidase (LOX; IMG-6442A, 
Imgenex, San Diego, CA), and prolyl-4-hydroxylase (P4H; bs-5090R, Bioss, Woburn, MA). 
A biotinylated secondary antibody (Jackson Immunoresearch, West Grove, PA) was added to 
all samples to allow for visualization using a 3,3′-Diaminobenzidine chromagen reaction 
(Vector Laboratories, Burlingame, CA). Negative controls for each secondary antibody were 
performed for each sample with no primary antibody.
For both histology stains and IHC, the anterior leaflet clear zone, anterior leaflet rough zone, 
and posterior mid-leaflet regions were imaged using a Leica DMLS upright light microscope 
(Buffalo Grove, IL). Herovici staining was imaged using white light, while picrosirius red 
stain images were conducted under both white light and polarized light in order to capture 
the birefringence of the constitutive collagen fibers.13,30 For Herovici and picrosirius red 
birefringence analysis, Image J software (NIH, Bethesda, MD) was used to first split images 
into their hue, saturation, and brightness components and then quantify the amount of red 
hue present as a percentage of total tissue area as described previously.43 IHC analysis was 
performed as previously described using Image J software to determine the percent of tissue 
area that stained positive for the antigen of interest compared to matched negative control (n 
= 6 to 8 for all staining).2
Materials Testing
Mechanical analysis was performed as described previously.18 Anterior clear zone, anterior 
rough zone, anterior radial, posterior circumferential, and posterior radial leaflet segments 
(each n = 6 to 8) and anterior basal, anterior marginal, posterior basal, and posterior 
marginal chordae (each n = 14 to 16, 2 of each type tested per valve) were tested with a pre-
determined uniaxial tensile testing protocol using an EnduraTEC ELF 3220 (Bose, Eden 
Prairie, MN).
In brief, thickness, width, and gauge length of the tissue segments were measured prior to 
testing. Testing was conducted in 37°C phosphate buffer saline. Tissue was preconditioned 
using ten load-unload triangle waves. A simple ramp load was then applied and held for 60 
seconds to measure stress relaxation. This evaluation was followed by a ramp unload, 10 
second rest period, five preconditioning cycles and a simple load-unload triangle wave to 
observe tissue hysteresis. The tissue segment was then stretched to failure. Any sections that 
failed prior to completion of the entire protocol were not included in the analysis.
Mechanical testing data was then converted from load and displacement to stress-strain 
curves for analysis conducted using MATLAB software (MathWorks, Natick, MA). Gauge 
length for each test was determined according to protocols developed from previously 
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described methods.8 Stress relaxation data was fit to a bi-phasic decay model and the fast 
and slow time constants were calculated. Hysteresis percentage was calculated by dividing 
the area between the loading and unloading curve by the total area under the loading curve. 
Elastic modulus was calculated from the slope of the second linear region of the bilinear 
stress-strain curve, extensibility was calculated as the x-intercept of the line defined by the 
elastic modulus, and the ultimate stress and strain were defined as the stress and strain 
values at the maximum stress obtained throughout failure tensile testing.
Biochemical Analysis
Biochemical analysis was conducted as previously described.18 Anterior clear zone, anterior 
rough zone, and posterior leaflet sections (n = 7 to 8) were weighed before and after 
lyophilization to determine hydration of tissues. After digestion in pepsin (Sigma-Aldrich, 
St. Louis, MO), samples were tested for collagen content using the Sircol Assay (Biocolor, 
Carrickfergus, United Kingdom). After digestion in both pepsin and Proteinase K 
(Calbiochem, Darmstadt, Germany), samples were tested for GAG content using the 
Blyscan Assay (Biocolor, Carrickfergus, United Kingdom). Colorimetric data was analyzed 
using a Spectramax M2 (Molecular Devices, Sunnyvale, CA) and compared to standard 
curves prepared using known quantities of rat-tail collagen or glucuronic acid for the Sircol 
or Blysacn assay, respectively. All values were normalized to dry weight of the tissue 
sample.
Statistical Analysis
Statistical analysis was performed using R Studio software (Version 0.98.953). Data are 
expressed as mean ± standard error or as percent difference of the means. Graphs are 
expressed as boxplots with outliers being defined by the 1.5 interquartile range rule. Unless 
otherwise stated, two-way ANOVA with post hoc Tukey Honestly Significant Difference test 
was performed to determine differences across condition groups (control vs. MVP and 
control vs. FMR) and tissue sections (i.e. anterior rough vs. anterior clear). When the 
patterns of results were inconsistent across tissue sections, individual one-way ANOVA with 
post hoc Tukey test was performed across condition groups to determine differences. Power 
analysis was performed to ensure appropriate sample size for all groups (1−β = 0.8). Results 
were considered significant at p < 0.05.
Results
Validation of Control Condition Valve Viability
No significant difference was found in valve thickness or DNA content comparing control 
condition to fresh valve tissues. In addition, observation of the layered structure of valve 
tissues using Movat pentachrome staining showed no phenotypic difference between valve 
tissues from the control condition or fresh sources. Cells isolated from control condition 
tissues were successfully cultured for two weeks on tissue culture plastic and demonstrated 
growth rates consistent with cells obtained from fresh tissues (data not shown).
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Hemodynamic Validation of Disease-Mimicking Conditions
Flow measurements obtained at the end of one-week culture showed moderate regurgitation 
in MVP (regurgitant fraction 35 ± 4%) and FMR (regurgitant fraction 20 ± 2%) conditions. 
In contrast, low regurgitation was observed and maintained in controls (regurgitant fraction 
11 ± 1%). Both conditions also experienced a significant increase from the degree of 
regurgitation at the initial setup to the final amount of regurgitation across the one-week 
culture (MVP: +13 ± 4%, p < 0.05; FMR: +8± 1%, p < 0.001, Student’s t test).
In addition, color Doppler echocardiography performed using the imaging flow loop after 
one-week culture confirmed that MVP condition valves displayed the characteristic 
eccentric regurgitant jet of prolapse and that FMR condition valves displayed the 
characteristic central jet of FMR (Figure 4 and Supplemental videos 1–3). Standard clinical 
echocardiogram measurements were also performed on the imaged valves. Regurgitant 
volumes obtained using a flow meter, vena contracta orifice area, and proximal isovelocity 
surface area (PISA) orifice area and regurgitant volume confirmed a non-regurgitant control 
condition and moderate regurgitation in both disease conditions. These measurements are 
summarized in Table 1.
MVP Condition
Composition—Sulfated GAG concentration was greater in MVP valve segments 
compared to controls (+37% anterior clear, +39% anterior rough, +72% posterior). MVP 
tissues also had greater hydration (+29% anterior clear, +33% anterior rough, +68% 
posterior). Immunohistochemistry showed a 188% greater level of collagen III expression in 
MVP posterior leaflets compared to controls, but no significant difference in anterior clear 
zone or anterior rough zone. MVP valve tissues were also significantly thicker than controls 
(+38% anterior clear, +49% anterior rough, +21% posterior circumferential, +43% anterior 
radial, +8% posterior radial). These results are summarized in Figure 5. Collagen content 
(Sircol Assay), MMP-1, Decorin, LOX, mature collagen (Herovici), and highly aligned 
collagen (picrosirius red) were analyzed and found to not be statistically significant.
Material Properties—MVP valve leaflets had a lower elastic modulus (−39% anterior 
clear, −59% anterior rough, −10% posterior circumferential, −14% anterior radial, −3% 
posterior radial) and lower ultimate stress (−50% anterior clear, −53% anterior rough, +2% 
posterior circumferential, −28% anterior radial, −39% posterior radial) than controls. In 
addition, the circumferentially oriented MVP leaflet segments had a significantly larger 
stress relaxation fast time constant (+6% anterior clear, +11% anterior rough, +6% posterior 
circumferential) compared to controls. This finding corresponds to greater viscosity over 
control tissues. Results are summarized in Figure 6.
FMR Condition
Composition—Compared to controls, FMR valve tissues had greater content of MMP-1, 
an interstitial collagenase involved in collagen degradation in remodeling tissues (+64% 
anterior clear, +73% anterior rough, +608% posterior). FMR valves also had greater 
expression of decorin, a small leucine-rich proteoglycan involved in collagen fibrillogenesis 
(+164% anterior clear, +64% anterior rough, +18% posterior), and LOX, an enzyme 
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responsible for collagen crosslinking (−15% anterior clear, +62% anterior rough, +193% 
posterior). Mature collagen content was also larger in FMR leaflets as captured by the 
percentage of red hue in the Herovici stain (+81% anterior clear, +57% anterior rough, 
+48% posterior). In addition, the amount of highly aligned collagen in FMR leaflets was 
lower than controls as measured by red birefringence of picrosirius red staining (−27% 
anterior clear, −36% anterior rough, −8% posterior). The Sircol analysis did not show a 
significant difference in overall collagen content between FMR and control valve tissues (p 
= 0.50). Results are shown in Figure 7. Collagen III, GAG concentration (Blyscan Assay), 
and hydration were analyzed and found not to be statistically significant.
Material Properties—FMR valve leaflets have a higher elastic modulus (+57% anterior 
clear, +48% anterior rough, +69% posterior circumferential, +17% anterior radial, +50% 
posterior radial) than control valves. Ultimate strain was lower in both radial FMR leaflet 
segments (−29% anterior radial, −46% posterior radial) and FMR chordae (−15% anterior 
basal, −9% posterior basal, −1% anterior marginal, −45% posterior marginal) when 
compared to control tissues. Extensibility was higher in circumferential FMR leaflets (+4% 
anterior clear, +13% anterior rough, +35% posterior), but lower in radial FMR leaflets 
(−48% anterior radial, −28% posterior radial) and chordae (−26% anterior basal, −17% 
posterior basal, +8% anterior marginal, −30% posterior marginal). Radial FMR leaflet 
segments also had a lower hysteresis percentage compared to controls (−35% anterior radial, 
−46% posterior radial), a sign of greater elasticity and lower viscosity in FMR tissues. 
Results are shown in Figure 8.
Discussion
Precise control of valve geometry allows for creation of clinically relevant disease 
hemodynamics
Using RUFLS, we have created the first sterile in vitro replication of mitral regurgitation. 
We previously established that dynamic culture of mitral valves in our organ culture system 
was significantly improved over static culture as comparable to fresh tissue.18 This previous 
study showed that valves cultured within RUFLS maintained cell viability and proliferation. 
In addition, the system maintained sterility throughout the culture period and the pH of 
media was maintained.17,18 However, that earlier work was limited in its ability to control 
annular and papillary muscle geometry. Previous systems in other labs have implemented 
precisely controlled geometry to recreate and investigate aspects of mitral valve disease in in 
vitro flow loops, but these studies were limited to non-sterile healthy valves without a long-
term culture period.6,25,41 In the work presented here, we aimed to replicate these 
advancements to better control papillary muscle positioning as well as annular diameter and 
shape, which allows for the first creation of mitral valve disease hemodynamics in a sterile 
in vitro system. By measuring and replicating the geometry of healthy valves in RUFLS, we 
are able to create a valve that is non-regurgitant throughout the one-week culture period. In 
addition, we confirmed that these improvements to RUFLS did not affect the previously 
established cell viability and proliferation of cultured tissues. Taking advantage of these 
improvements, we can recreate MVP and FMR-like valve geometries with moderate 
regurgitation and characteristic regurgitant color Doppler jet profiles in vitro by 
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manipulating the geometry of the valve from its neutral positioning. In addition, our 
measurements of regurgitation hemodynamics, assessed via echocardiography in our 
imaging flow loop, confirm the moderate regurgitation found in our sterile system flow 
meter measurements. We are therefore able to culture healthy valves in hemodynamic 
conditions that mimic clinical disease, investigating how the valve responds in a causal and 
controlled fashion. As a result, we can conclude that differences in tissues cultured in control 
versus disease conditions are due to the hemodynamic alterations mimicking the disease. 
This is an advantage of in vitro organ culture over clinical studies of diseased tissues, which 
cannot differentiate the impact of hemodynamic environment on tissue remodeling from 
underlying tissue pathology independent of environment.
MVP conditioned valve tissues undergo myxomatous remodeling
After one-week culture in the slack conditions resembling MVP, valve tissues showed 
characteristics of myxomatous remodeling. In the clinical presentation of mitral 
regurgitation, the most compelling evidence for myxomatous remodeling includes an 
elevation in GAG content,21,22 higher amounts of type III collagen,10 and a reduction in 
elastic modulus and ultimate stress compared to healthy valves.3,4,22,23 Our MVP-
conditioned valves have a similar set of differences from controls, with more reticular, type 
III collagen in the posterior leaflet, greater hydration, and elevated GAG content. The lack of 
significant findings amongst the collagen remodeling and synthesis enzymes investigated 
suggests that the low-tension environment of MVP results in a myxomatous phenotype 
through increased GAG and reticular collagen accumulation and not through extensive 
turnover of the existing collagen architecture. However, this does not preclude collagen 
enzyme involvement later in the remodeling process. The combination of these extracellular 
matrix changes results in altered material behavior in our valves including a reduction in 
elastic modulus and ultimate stress. In addition, a higher stress relaxation fast time constant 
in leaflets corresponds to more viscous behavior of MVP-conditioned valves compared to 
controls, consistent with greater GAG content.
Our ability to condition healthy valves to replicate these findings using hemodynamic 
manipulations alone helps to clarify the possible mechanisms of MVP pathology in a way 
that was previously impossible to obtain. Our findings support the hypothesis that the 
valvular interstitial cells of the mitral valve respond to the low-tension tissue conditions of 
MVP hemodynamics in a myxomatous manner, decreasing the tissue tensile strength in 
accordance with the hemodynamic demands placed on the tissue.
FMR condition valve tissues undergo fibrotic remodeling
After one-week culture in the high-tension environment of the FMR condition, valve tissues 
showed characteristics of fibrotic remodeling. Clinically, FMR tissues have been reported as 
having greater collagen content,20 resulting in mechanically stiffer tissues compared to 
healthy controls.19 Animal studies simulating FMR using tachycardia,47 tethering,12 and 
ischemia42 also showed increases in collagen turnover, deposition, and procollagen I, 
respectively, consistent with fibrotic remodeling. While we did not find an elevation in 
collagen content, we did observe greater expression of factors involved with collagen 
fibrillar assembly (decorin), crosslinking (LOX), and degradation (MMP-1), as well as 
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increases in collagen maturity (Herovici staining). Taken together, these results suggest that 
FMR conditioned tissues are undergoing fibrotic remodeling.
The reorganization of collagen architecture within the valve plays an important role during 
fibrotic remodeling. The combination of smaller amounts of highly aligned collagen as 
measured by picrosirius red staining and increased presence of LOX, a collagen crosslinking 
enzyme, provides support for reorganization. This interpretation is also supported by the 
observed changes in material properties; FMR-conditioned tissues were stiffer, more brittle, 
less extensible, and less viscous than controls in the radial direction. These findings are 
consistent with the material property differences reported for human FMR leaflets, which 
were predominantly observed in radial specimens, oriented perpendicularly to the main 
collagen orientation in the mitral valve.32 Collagen reorganization can also explain the larger 
extensibility in the circumferential direction, as a decrease in collagen alignment would 
necessitate more strain in order to incorporate and uncrimp the less aligned collagen 
components of the extracellular matrix.
These material properties also support the hypothesis that fibrotic-type remodeling is in 
response to the higher tension placed on valves by the hemodynamic conditions and 
tethering of FMR. Additionally, a majority of the observed mechanical alterations occurred 
in the radial direction, which experiences higher tension under tethering conditions. Also, 
larger elevations in MMP-1, LOX, and elastic modulus, as well as larger reductions in 
ultimate strain and hysteresis percentage, occurred in the posterior leaflet. As the posterior 
leaflet is under the least tension during healthy valve motion, finding that it reacts most 
strongly to high-tension FMR tethering demonstrates the effect of elevated tension on valve 
remodeling. This provides support for the hypothesis that mitral valve interstitial cells are 
responding to FMR hemodynamics by remodeling the extracellular matrix in a manner that 
increases stiffness and brittleness and decreases extensibility and viscosity of the valve. It 
also supports the previous findings that the mitral valve is not a passive actor in functional 
disease, and is physiologically altered as a result of the clinical setting seen in FMR.20
Implications of disease hemodynamics for remodeling
Both MVP and FMR are multifactorial disease processes. MVP has a wide variety of 
molecular and genetic mechanisms that may impact disease processes,14 while FMR can 
result from a variety of causes of left ventricular regional or global dysfunction.44 The final 
common pathway of both, however, is a regurgitant valve whose hemodynamic environment 
places aberrant mechanical forces on valve tissues throughout the cardiac cycle. By 
demonstrating that previously healthy valves placed in MVP and FMR hemodynamic 
conditions undergo myxomatous remodeling and fibrotic remodeling respectively, we have 
established a role for altered mechanics in the progression of mitral regurgitation.
These findings give insight to the development of mitral disease and how mitral tissues 
respond to alterations in hemodynamic and geometric conditions. While previous clinical 
studies have characterized these tissues in end-stage disease,10,19 and animal studies have 
looked at the impact that imposed disease models in a physiological system have on the 
mitral valve,12,47 our system allows for the investigation of the impact of isolated 
hemodynamic changes on valve tissues. By conditioning valves in our system and 
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comparing to controls cultured under identical pressure and heart rate conditions, we are 
able to establish a direct, causal relationship between altered hemodynamics created by our 
disease condition geometries and alterations that occur in tissues as a result. The dramatic 
differences observed show the profound impact that disease hemodynamics can impart upon 
valve remodeling, and the short, one-week culture time demonstrates that these changes 
happen quickly. Collectively, these findings suggest that the acute, large magnitude 
geometric changes imposed on valves in our system create an accelerated disease model of 
mitral regurgitation. Although mitral valve disease is typically a slowly developing chronic 
condition, the results of this work establish that the mitral valve is highly sensitive to 
changing mechanics. This mechanosensitivity could have implications for more acute forms 
of mitral regurgitation, such as ischemic mitral regurgitation. Ischemic mitral regurgitation 
occurs as a result of left ventricular dysfunction due to a myocardial infarction and is a form 
of acute functional mitral regurgitation.5 In addition, there is much debate about the best 
clinical practice regarding the treatment of ischemic mitral regurgitation, especially in 
moderate and severe disease.9,50 While clinical samples of mitral valve tissues from these 
patients have yet to be studied in the early stages of the disease, the left atria and left 
ventricle remodel rapidly in the weeks following infarct, suggesting a global cardiovascular 
remodeling event.5 The results of our study suggest that such a hemodynamic alteration 
could also cause rapid remodeling of the mitral valve tissues.
Additionally, the increases in regurgitation observed in both disease models throughout the 
culture period provide evidence that valve remodeling worsens disease progression. In other 
words, the valves are not responding to the amount of regurgitant flow, but rather to the 
mechanical load placed on the valves as a result of valve geometry and hemodynamics. This 
load then leads to tissue remodeling that worsens the regurgitation. These findings also 
provide support for the hypothesis that the mitral valve is an active participant in the disease 
process of both organic (MVP) and functional (FMR) valve disease. Additionally, this 
interaction challenges the notion that valve disease is distinctly an organic or functional 
phenomenon. While it is still useful to classify mitral valve disease in terms of whether the 
inciting pathologic incident was intrinsic to the valve (organic) or due to disturbances in 
valve geometry (functional), our findings suggest that the disease progression is a dynamic 
interaction between the compositional properties of the valves and the resulting forces. 
Intervention, if it restores native valve geometry as a part of repair, could respond in a 
similarly rapid fashion. Recent findings suggest that when repairs of ischemic mitral 
regurgitation do fail, the increasing post-repair regurgitation is correlated with the presence 
of leaflet tethering, in isolation of regurgitation volume after surgery.31 This finding supports 
our finding that the mitral valve remodels -- in a way that results in increased regurgitation -- 
when placed under pathologic mechanics such as the tethering of leaflets. Several 
experimental devices have aimed to address the concern that eliminating regurgitation alone 
is not adequate for long-term repair if the valve is still experiencing altered mechanics. 
Devices such as the Coapsys16 and Mitral Touch48 aim to reposition the papillary muscles of 
the mitral valve in order to create a more lasting treatment for FMR. While further study is 
needed to explore how rapidly and in what context myxomatous and fibrotic remodeling can 
be reversed, the findings of dynamic adaptation of the valve in response to changing 
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mechanical environment does lend support to the idea that removing the pathologic 
mechanical environment could quickly impact valve remodeling.
The re-creation of mitral regurgitation in vitro is a useful method to evaluate the effect of 
altered tension on mitral valve leaflet remodeling, so long as the results are considered 
within the appropriate context. For example, RUFLS cannot replicate the systemic 
physiologic response to the disease geometries that were imposed on healthy mitral valves to 
create our models. This limitation includes the lack of systemic cardiovascular response to 
reduce the imposed regurgitation and alterations in blood pressure that would result. 
Physiological responses would also include cellular or healing responses that would initiate 
from sources outside the valve in response to the disease state. However, although this 
system lacks physiologic response that would be observed clinically or in an animal model, 
it does allow for the control of the hemodynamic environment that would not be possible in 
a physiologically responsive system. This control allows for direct conclusions on how 
disease hemodynamics affects living valve tissues. A limitation of the RUFLS system is the 
sub-physiological flow of 3 L/min, which was the result of constraints placed on different 
RUFLS components due to the requirements of sterile culture. This lower flow rate reduces 
shear stress experienced by valve leaflets within our system and could affect the response of 
valves as a result. Another limitation of this study is the use of a flat annulus during culture. 
The native annulus is saddle shaped, and this shape has been shown to have an impact on 
valve function throughout the cardiac cycle.28,40 Additionally, while porcine valves provide 
the closest animal model of human mitral valves, slight anatomical differences could affect 
the translation of these findings to human disease.
By exploring the impact of mechanical forces on remodeling in two distinct disease 
conditions, our in vitro systems provide an experimental paradigm for the further 
investigation of MVP and FMR remodeling and ways to reverse it. This work establishes the 
dynamic interaction between composition, mechanical properties of valve tissues, and the 
mechanical environment of regurgitation, and how the interplay between these three factors 
leads to the progression of mitral regurgitation. The highly controlled and modular nature of 
valve models and our ability to perform functional imaging of the valve constructs will allow 
us to explore the independent effects of additional geometric, hemodynamic, or 
pharmacological alterations to control, MVP, and FMR valves in a timely fashion without 
the confounding impacts of systemic physiological responses. While clinical and animal 
studies remain invaluable resources for disease investigation, the establishment of in vitro 
disease conditioning provides a highly controlled mechanism for investigating disease 
progression and potentially reversal.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic of Rice University Flow Loop System (RUFLS). Solid arrows show the flow of 
media through the bioreactor system. Dashed arrows show the flow of information to and 
from RUFLS and the computer DAQ system. LV = left ventricle. DAQ = data acquisition 
system.
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Figure 2. 
MVP & FMR Condition Creation. FMR condition created by (A) apical and (D) lateral 
displacement of papillary muscles from the neutral position (dashed line), as well as (D) 
65% greater annular area compared to (E) control annulus. (C, F) MVP model created by 
basal displacement of papillary muscles from neutral position (dashed line). (B, E) Control 
model created by placing valve in neutral position. FMR = functional mitral regurgitation; 
MVP = mitral valve prolapse.
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Figure 3. 
Valve Sections. Tissues were mechanically tested in radial and circumferential directions 
and the anterior leaflet was divided into clear and rough zones corresponding to the absence 
or presence of chordae tendineae.
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Figure 4. 
Analysis of Valve Models. Using the Imaging Flow Loop, (A) control valves showed no 
regurgitant jet. (B) MVP valves showed characteristic eccentric regurgitant jet (red, left-
oriented back flow). (C) FMR valves showed characteristic central jet. Photos (bottom row) 
are screen shots taken during end of systole from imaging flow loop videos. (D) Controls 
with proper coaptation of leaflets. (E) MVP posterior leaflet prolapsing (red arrows 
emphasize prolapsing leaflet). (F) FMR leaflets tethering resulting in incomplete coaptation. 
n = 2. Scale bar = 1 cm. FMR = functional mitral regurgitation; MVP = mitral valve 
prolapse.
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Figure 5. 
Myxomatous Characteristics Elevated in MVP. MVP leaflets have higher concentrations of 
(A) Col3 as calculated by the percent area stained using immunohistochemistry. In addition, 
(B) MVP leaflets have higher concentrations of GAGs, (C) are thicker, and (D) have greater 
hydration compared to controls. Representative pictures of DAB-based 
immunohistochemistry staining of controls (top picture), negative controls (no primary 
antibody; insert, top picture), and MVP valves (bottom picture) are shown. n = 6 to 8. Scale 
bar = 100 μm. ANOVA with post hoc Tukey’s HSD test used for significance. * = p < 0.05; 
** = p < 0.01; *** = p < 0.001. Col3 = collagen III; GAG = glycosaminoglycan; MVP = 
mitral valve prolapse; Neg = negative control.
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Figure 6. 
Mechanical Analysis of MVP Valves. MVP leaflets have (A) lower elastic modulus and (B) 
lower ultimate stress overall. In addition, MVP leaflets have (C) a larger stress relaxation 
fast time constant than controls in the circumferential direction. n = 6 to 8 leaflets, 14 to 16 
chordae. ANOVA with post hoc Tukey’s HSD test used for significance. * = p < 0.05; ** = p 
< 0.01; *** = p < 0.001.
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Figure 7. 
Fibrotic Remodeling Characteristics Elevated in FMR. FMR leaflets have higher 
concentrations of (A) MMP-1, (B) decorin, and (C) lysyl oxidase as calculated by the 
percent area stained using immunohistochemistry (graphs). In addition, FMR leaflets have 
(D) more mature collagen as measured by red hue in Herovici staining but (E) less aligned 
collagen as measured by red birefringence in picrosirius red staining. (F) Representative, 
higher resolution images of picrosirius red staining in polarized and white light are shown, 
along with representative pictures of (A–C) DAB-based immunohistochemistry and (D) 
Herovici staining of controls and FMR valves. n = 6 to 8. Scale bar = 100 μm (A–E) or 800 
μm (F). ANOVA with post hoc Tukey’s HSD test used for significance. * = p < 0.05; ** = p 
< 0.01; *** = p < 0.001. FMR = functional mitral regurgitation; MMP-1 = matrix 
metalloproteinase 1; Neg = negative control.
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Figure 8. 
Mechanical Analysis of FMR Valves. FMR leaflets had (A) higher elastic modulus than 
controls. In the circumferential direction, FMR valves had (B) higher extensibility. In the 
radial direction, FMR leaflets had (C) lower extensibility, (D) lower ultimate strain, and (E) 
lower hysteresis percentage than controls. FMR chordae had (F) less extensibility and (G) 
lower ultimate strain than controls. n = 6 to 8 leaflets, 14 to 16 chordae. ANOVA with post 
hoc Tukey’s HSD test used for significance. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
FMR = functional mitral regurgitation.
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Table 1
Hemodynamic Validation of Regurgitant Conditions Using Echocardiography.
Condition Control MVP FMR
Flowmeter regurgitant flow volume (ml) - 40 43
Leaflet coaptation length (mm) 16 9 6
Vena contracta
 Long axis (mm) - 5 4
 Short axis (mm) - 4 11
 Area (cm2) - 0.34 0.29
PISA effective regurgitant orifice area (cm2) - 0.3 0.2*
PISA derived regurgitant volume (ml) - 27 37
*
PISA method well recognized to underestimate effective regurgitant orifice area for FMR1,49
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